Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
5.91
+0.12 (2.07%)
At close: Jun 25, 2025, 4:00 PM
5.90
-0.02 (-0.34%)
Pre-market: Jun 26, 2025, 8:14 AM EDT
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $257.88K in the quarter ending March 31, 2025, with 103.32% growth. This brings the company's revenue in the last twelve months to $3.69M, down -39.87% year-over-year. In the year 2024, Coya Therapeutics had annual revenue of $3.55M, down -40.79%.
Revenue (ttm)
$3.69M
Revenue Growth
-39.87%
P/S Ratio
25.39
Revenue / Employee
$460,638
Employees
8
Market Cap
99.01M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
Dec 31, 2023 | 6.00M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
COYA News
- 8 days ago - Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025 - Business Wire
- 24 days ago - Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations - Business Wire
- 5 weeks ago - Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Business Wire
- 6 weeks ago - Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update - Business Wire
- 7 weeks ago - Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025 - Business Wire
- 7 weeks ago - Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors - GlobeNewsWire
- 2 months ago - Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release - Seeking Alpha
- 2 months ago - Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - Business Wire